prostate epithelial cells Search Results


prostate epithelial cell growth kit  (ATCC)
94
ATCC prostate epithelial cell growth kit
Prostate Epithelial Cell Growth Kit, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Prostate+Epithelial+Cell+Growth+Kit/pmc07416765-477-13-18
Average 94 stars, based on 1 article reviews
prostate epithelial cell growth kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
prostate epithelial cell culture medium  (Innoprot Inc)
92
Innoprot Inc prostate epithelial cell culture medium
Prostate Epithelial Cell Culture Medium, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Prostate+Epithelial+Cell+Medium/pm36806993-72-6-11
Average 92 stars, based on 1 article reviews
prostate epithelial cell culture medium - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
prec basal medium  (ATCC)
99
ATCC prec basal medium
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Prec Basal Medium, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Prostate+Epithelial+Cell+Basal+Medium/pm30659180-224-10-13
Average 99 stars, based on 1 article reviews
prec basal medium - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
human normal prostate epithelial cell line prec  (ATCC)
99
ATCC human normal prostate epithelial cell line prec
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Human Normal Prostate Epithelial Cell Line Prec, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Primary+Prostate+Epithelial+Cells%3B+Normal%2C+Human/pmc05722564-113-0-15
Average 99 stars, based on 1 article reviews
human normal prostate epithelial cell line prec - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
basal mediums  (ATCC)
92
ATCC basal mediums
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Basal Mediums, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Prostate+Epithelial+Cell+Basal+Medium/pmc06801752-113-27-29
Average 92 stars, based on 1 article reviews
basal mediums - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
human prostate cancer cell line lncap  (ATCC)
94
ATCC human prostate cancer cell line lncap
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Human Prostate Cancer Cell Line Lncap, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Primary+Prostate+Epithelial+Cells%3B+Normal+Human/pmc02671895-86-1-18
Average 94 stars, based on 1 article reviews
human prostate cancer cell line lncap - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human bone metastasis derived prostate cancer pc 3 cells  (ATCC)
93
ATCC human bone metastasis derived prostate cancer pc 3 cells
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Human Bone Metastasis Derived Prostate Cancer Pc 3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Human+prostate+epithelial+cell+line+derived+from+prostate+cancer+specimen%2C+1535-CP1TX%2C+Passage+20/pmc06352880-31-0-7
Average 93 stars, based on 1 article reviews
human bone metastasis derived prostate cancer pc 3 cells - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
human prostate tissue  (ATCC)
92
ATCC human prostate tissue
Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and <t>PrEC</t> (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and <t>luminal</t> <t>prostate</t> cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments
Human Prostate Tissue, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Human+prostate+epithelial+cell+line+derived+from+normal+prostate+tissue%2C+1542-NPTX%2C+Passage+18/pmc07041748-180-13-20
Average 92 stars, based on 1 article reviews
human prostate tissue - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
human prostate epithelial cell line  (ATCC)
91
ATCC human prostate epithelial cell line
PGAM1 expression in prostate cancer tissues and prostate cancer cell lines. ( a ) The immunohistochemistry image of the whole TMA (scale bar = 1.5 mm). Representative immunohistochemistry images of PGAM1 protein expression from ( a ) with high intensity ( b ) in prostate cancer tissue (D7, scale bar = 0.2 mm), with intermediate intensity ( c ) in prostate cancer tissue (H7, scale bar = 0.2 mm), and with low intensity ( d ) in prostate cancer tissue (E4, scale bar = 0.2 mm). The percentage of PGAM1 positive cells in D7 is 90%, in H7 is 70%, and in E4 is 15%. Therefore, the percentage score of the case in D7 is 3 and its total protein expression score is 3 × 3 = 9. The percentage score of the case in H7 is 2 and its total protein expression score is 2 × 2 = 4. The percentage score of the case in E4 is 1 and its total protein expression score is 1 × 1 = 1. ( e ) Part of C14 from ( a ) with a magnification of 400× (scale bar = 50 μm). ( f ) Western blotting of PGAM1 protein expression in prostate cancer cell lines and normal prostate <t>epithelial</t> cell lines. PGAM1: phosphoglycerate mutase 1; TMA: tissue microarray.
Human Prostate Epithelial Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Human+prostate+epithelial+cell+line+1519+CPTX/pmc05858104-22-16-22
Average 91 stars, based on 1 article reviews
human prostate epithelial cell line - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
human primary prostate epithelial cell line hprepc  (Cell Applications Inc)
90
Cell Applications Inc human primary prostate epithelial cell line hprepc
PGAM1 expression in prostate cancer tissues and prostate cancer cell lines. ( a ) The immunohistochemistry image of the whole TMA (scale bar = 1.5 mm). Representative immunohistochemistry images of PGAM1 protein expression from ( a ) with high intensity ( b ) in prostate cancer tissue (D7, scale bar = 0.2 mm), with intermediate intensity ( c ) in prostate cancer tissue (H7, scale bar = 0.2 mm), and with low intensity ( d ) in prostate cancer tissue (E4, scale bar = 0.2 mm). The percentage of PGAM1 positive cells in D7 is 90%, in H7 is 70%, and in E4 is 15%. Therefore, the percentage score of the case in D7 is 3 and its total protein expression score is 3 × 3 = 9. The percentage score of the case in H7 is 2 and its total protein expression score is 2 × 2 = 4. The percentage score of the case in E4 is 1 and its total protein expression score is 1 × 1 = 1. ( e ) Part of C14 from ( a ) with a magnification of 400× (scale bar = 50 μm). ( f ) Western blotting of PGAM1 protein expression in prostate cancer cell lines and normal prostate <t>epithelial</t> cell lines. PGAM1: phosphoglycerate mutase 1; TMA: tissue microarray.
Human Primary Prostate Epithelial Cell Line Hprepc, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Human+Prostate+Epithelial+Cells%3A+HPrEpC/pm30185663-344-2-12
Average 90 stars, based on 1 article reviews
human primary prostate epithelial cell line hprepc - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
human prostate epithelial cells hprepic  (Innoprot Inc)
93
Innoprot Inc human prostate epithelial cells hprepic
Graphical representation of miRNA expression levels in the <t>HPrEpiC</t> cell line isolated from normal human prostate tissue. MiRNA expression was analyzed using RT-qPCR and compared to a control group that was not treated. The RNU6 housekeeping gene was used as a reference for normalization and relative expression was calculated using the ΔCT expression/ΔCT control ratio. The cells were irradiated in three doses of 2.5 Gy, with the first dose being 1 × 2.5 Gy, the second dose being 2 × 2.5 Gy, and the third dose being 3 × 2.5 Gy. N = 2.
Human Prostate Epithelial Cells Hprepic, supplied by Innoprot Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/prostate+epithelial+cells/Human+Prostate+Epithelial+Cells/pmc10931958-153-23-31
Average 93 stars, based on 1 article reviews
human prostate epithelial cells hprepic - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and PrEC (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and luminal prostate cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments

Journal: Nature communications

Article Title: LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation.

doi: 10.1038/s41467-018-08153-2

Figure Lengend Snippet: Fig. 5 LEADR regulates basal–luminal differentiation. a Bright-field images showing morphological changes occurring in RWPE-1 (left) and PrEC (right) cells (day 3) upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4c. b qRT-PCR showing changes in basal and luminal cytokeratins in RWPE-1 or PrEC cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Mean + s.d. plotted. c Western blots showing changes in basal/luminal cytokeratins in RWPE-1 (left) or PrEC (right) cells upon LEADR silencing by siLEADR (top) or gapLEADR (bottom). Vinculin used as loading control. d Immunofluorescence showing cytoplasmic re-localization of p63 (green) upon LEADR silencing in RWPE-1 cells by siLEADR (top) or gapLEADR (bottom). Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images are reported in Supplementary Fig. 4d. e Western blots showing changes in Androgen Receptor (AR) expression in PrEC cells upon LEADR silencing by siLEADR (left) or gapLEADR (right). GAPDH used as loading control. f Immunofluorescence showing AR (red) expression in PrEC cells upon LEADR silencing by siLEADR, in the presence or absence of simultaneous DHT stimulation. Nuclei counterstained with DAPI (blue). Scale bar, 50 µm. Full-size images reported in Supplementary Fig. 4g. g ELISA-based quantification of PSA in the conditioned media of PrEC cells silenced for LEADR expression by siLEADR (±DHT). Mean + s.d. (n = 2) plotted. h Heatmap (bottom) of the normalized enrichment score (NES) for luminal and basal custom gene sets (obtained from gene- expression data of frankly basal and luminal prostate cells from the indicated datasets) in RWPE-1 cells upon knockdown of LEADR and/or miR-205 (the latter abrogated using an antisense LNA-modified oligomer, LNA205). Bar plot of differential luminal/basal NES is reported (top). Mean + s.d. (n = 4) plotted. i Plot showing propensity of wild type (wt), LEADR-overexpressing and CRISPRed RWPE-1 cells to differentiate toward luminal phenotype (measured by qRT-PCR and expressed as KRT18/KRT5 ratio) upon culturing in media with increasing differentiative potential (n = 3). ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 (Student’s t test). Source data are provided as a Source Data file, together with n of all experiments

Article Snippet: The normal primary prostate epithelial cells (PrEC) were grown in PrEC basal medium (ATCC; PCS-440-030) supplemented with PrEC growth kit (ATCC; PCS-440-040).

Techniques: Quantitative RT-PCR, Western Blot, Control, Expressing, Enzyme-linked Immunosorbent Assay, Gene Expression, Knockdown

PGAM1 expression in prostate cancer tissues and prostate cancer cell lines. ( a ) The immunohistochemistry image of the whole TMA (scale bar = 1.5 mm). Representative immunohistochemistry images of PGAM1 protein expression from ( a ) with high intensity ( b ) in prostate cancer tissue (D7, scale bar = 0.2 mm), with intermediate intensity ( c ) in prostate cancer tissue (H7, scale bar = 0.2 mm), and with low intensity ( d ) in prostate cancer tissue (E4, scale bar = 0.2 mm). The percentage of PGAM1 positive cells in D7 is 90%, in H7 is 70%, and in E4 is 15%. Therefore, the percentage score of the case in D7 is 3 and its total protein expression score is 3 × 3 = 9. The percentage score of the case in H7 is 2 and its total protein expression score is 2 × 2 = 4. The percentage score of the case in E4 is 1 and its total protein expression score is 1 × 1 = 1. ( e ) Part of C14 from ( a ) with a magnification of 400× (scale bar = 50 μm). ( f ) Western blotting of PGAM1 protein expression in prostate cancer cell lines and normal prostate epithelial cell lines. PGAM1: phosphoglycerate mutase 1; TMA: tissue microarray.

Journal: Asian Journal of Andrology

Article Title: Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion

doi: 10.4103/aja.aja_57_17

Figure Lengend Snippet: PGAM1 expression in prostate cancer tissues and prostate cancer cell lines. ( a ) The immunohistochemistry image of the whole TMA (scale bar = 1.5 mm). Representative immunohistochemistry images of PGAM1 protein expression from ( a ) with high intensity ( b ) in prostate cancer tissue (D7, scale bar = 0.2 mm), with intermediate intensity ( c ) in prostate cancer tissue (H7, scale bar = 0.2 mm), and with low intensity ( d ) in prostate cancer tissue (E4, scale bar = 0.2 mm). The percentage of PGAM1 positive cells in D7 is 90%, in H7 is 70%, and in E4 is 15%. Therefore, the percentage score of the case in D7 is 3 and its total protein expression score is 3 × 3 = 9. The percentage score of the case in H7 is 2 and its total protein expression score is 2 × 2 = 4. The percentage score of the case in E4 is 1 and its total protein expression score is 1 × 1 = 1. ( e ) Part of C14 from ( a ) with a magnification of 400× (scale bar = 50 μm). ( f ) Western blotting of PGAM1 protein expression in prostate cancer cell lines and normal prostate epithelial cell lines. PGAM1: phosphoglycerate mutase 1; TMA: tissue microarray.

Article Snippet: Four human PCa cell lines, PC-3, 22Rv1, DU145, and LNCap (ATCC, Manassas, VA, USA), and a human prostate epithelial cell line, RWPE1 (ATCC), were used in this study.

Techniques: Expressing, Immunohistochemistry, Western Blot, Microarray

Graphical representation of miRNA expression levels in the HPrEpiC cell line isolated from normal human prostate tissue. MiRNA expression was analyzed using RT-qPCR and compared to a control group that was not treated. The RNU6 housekeeping gene was used as a reference for normalization and relative expression was calculated using the ΔCT expression/ΔCT control ratio. The cells were irradiated in three doses of 2.5 Gy, with the first dose being 1 × 2.5 Gy, the second dose being 2 × 2.5 Gy, and the third dose being 3 × 2.5 Gy. N = 2.

Journal: International Journal of Molecular Sciences

Article Title: Radiotherapy Metastatic Prostate Cancer Cell Lines Treated with Gold Nanorods Modulate miRNA Signatures

doi: 10.3390/ijms25052754

Figure Lengend Snippet: Graphical representation of miRNA expression levels in the HPrEpiC cell line isolated from normal human prostate tissue. MiRNA expression was analyzed using RT-qPCR and compared to a control group that was not treated. The RNU6 housekeeping gene was used as a reference for normalization and relative expression was calculated using the ΔCT expression/ΔCT control ratio. The cells were irradiated in three doses of 2.5 Gy, with the first dose being 1 × 2.5 Gy, the second dose being 2 × 2.5 Gy, and the third dose being 3 × 2.5 Gy. N = 2.

Article Snippet: PC3, DU145, and LNCaP cell lines were provided by the Cancer Biology and Epigenetics Group at the Portuguese Oncology Institute of Porto, and human prostate Epithelial cells (HPrEpiC) were acquired from Innoprot (Innovative Technologies in Biological Systems, Derio, Spain).

Techniques: Expressing, Isolation, Quantitative RT-PCR, Irradiation

MiRNA expression in radiation response in prostate cancer cell lines. With regard to the data presented from our study, the results of the 3rd day of the study, i.e., 3 × 2.5 Gy, were taken into account.

Journal: International Journal of Molecular Sciences

Article Title: Radiotherapy Metastatic Prostate Cancer Cell Lines Treated with Gold Nanorods Modulate miRNA Signatures

doi: 10.3390/ijms25052754

Figure Lengend Snippet: MiRNA expression in radiation response in prostate cancer cell lines. With regard to the data presented from our study, the results of the 3rd day of the study, i.e., 3 × 2.5 Gy, were taken into account.

Article Snippet: PC3, DU145, and LNCaP cell lines were provided by the Cancer Biology and Epigenetics Group at the Portuguese Oncology Institute of Porto, and human prostate Epithelial cells (HPrEpiC) were acquired from Innoprot (Innovative Technologies in Biological Systems, Derio, Spain).

Techniques: Expressing, Irradiation, Functional Assay